In KRAS mutant lung and pancreatic cancer, mutant KRAS transcriptionally activates NRF2, a principal modulator of cellular redox, resulting in a reduced intracellular ROS level and leading to increased glutamine dependency [32,33]. Here, KRAS is linked to pancreatic neoplasm.